Compare Merck & Co., Inc. (MRK) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Teucrium Soybean Fund — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while Teucrium Soybean Fund trades at $25.86. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Teucrium Soybean Fund pays none. Which is the better fit depends on your goals.
| MRK | SOYB | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.52 | $25.88 |
52-Week Low | $77.60 | $21.07 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.
The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.
SOYB is trading at $25.88, up 1.53% today with strong technical momentum as moving averages signal bullish sentiment. The stock shows mixed oscillator readings with RSI suggesting potential overbought conditions. Recent agricultural sector news highlights potential tailwinds from China's $17 billion crop purchase commitment through 2028, which could benefit agricultural companies.
The stock presents bullish technical positioning but requires fundamental validation through upcoming earnings reports. Key risks include commodity price volatility and execution challenges. Upside potential exists if the company can capitalize on agricultural export opportunities, though investors should await financial metric updates for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
